Cancer epigenomics

Emerging evidence highlights the impossibility to ascribe the whole tumor heterogeneity merely to the genetic signature of tumor cells, hence making unfeasible to predict responses to existing therapies or prioritize the search for new and/or repurposed ones. Epigenetic control of cell identity is a frequent altered feature in tumor cells, making this research field progressively assuming a relevant role in cancer biology. In this field, DEO researchers have achieved important goals, unveiling the general mechanisms as well as specific targets and biomarkers exploitable from a therapeutic point of view.

First demonstration of the effects of oncogene expression on chromatin

Transcriptional and chromatin-mediated mechanisms controlling inflammatory gene expression and transcriptional mechanisms in cancer

Enhancer-dysregulation by histone-methyltransferases in melanomas

Elucidation of the role of the Polycomb 31 family of chromatin regulators in brain tumor formation (gliomagenesis) and cell reprogramming

Role of SET7/9 methyltransferase in p53 dependent DNA damage response

Developmental roles of the Jmjd3 histone demethylase oncogene

Oncogenic WNT Signalling is Sustained by Polycomb Activity in Intestinal Tumours

Control of Enhancers Fidelity by the Oncogene EZH2

Repressive Epigenetic Mark Preserves Undifferentiated Identity of Leukemic Cells

Oncogenic Polycomb Activities Directly Control DNA replication

Our site uses cookies for better browsing usability and statistics on its use. If you want to learn more, or refuse consent to all or some cookies, click here.